Upperton’s world leading expertise in biomolecule conjugation chemistry and especially albumin chemistry offers three drug delivery technologies with unique advantages:

• Production of nano-sized particles from peptides, proteins and other biomolecules
• Unique advantages include size-control, preservation of molecule’s structural and functional integrity, simplicity and scalability of production process.
• Nanoparticles can be made from active molecules or from carrier proteins to be loaded with drugs.
• Technology has been demonstrated with recombinant albumin*, transferrin, Apolipoprotein A-1, and monoclonal antibodies

More information on rP-nano^TM: technology | applications | collaborations

• Drugs, peptides or other molecules can bind naturally or be attached covalently to carrier proteins like albumin or transferrin.
• Upperton uses the unique properties of albumin or transferrin to design the most efficient and suitable linking chemistry for a given purpose/drug.
• Drugs linked to e.g. albumin or albumin nanoparticles can dramatically improve pharmacokinetic and pharmacodynamic properties.
• Linking technology has been demonstrated with 99mTc, Gadolinium, Methotrexate, and Doxorubicin.

More information on rP-conjugate^TM: technology | applications

• Upperton’s patented rP-target^TM technology chemically links monoclonal antibodies to drug loaded albumin or albumin nanoparticles.
• Drug loaded albumin molecules or nanoparticles can thus be targeted to specific sites.
• Several drug loaded albumin molecules can be linked to a single monoclonal antibody, increasing delivery efficiency.

More information on rP-target^TM: click here

  Contact us to discuss your requirements